A 34-year-old male from rural Maharashtra presents to the district hospital with a 3-month history of progressive weight loss, chronic diarrhea, and recurrent oral candidiasis. He reports unprotected sexual contact with multiple partners 18 months ago. On examination, he is cachectic with generalized lymphadenopathy. CD4 count is 185 cells/μL. HIV ELISA is positive, confirmed by Western blot. The treating physician initiates antiretroviral therapy (ART) as per National AIDS Control Programme (NACP) guidelines. Which of the following is the MOST appropriate first-line ART regimen according to current NACP-IV guidelines for this patient?

Explanation

## NACP-IV First-Line ART Regimen Selection **Key Point:** NACP-IV (2017 onwards) recommends **Tenofovir (TDF) + Lamivudine (3TC) + Efavirenz (EFV)** as the preferred first-line regimen for all adults initiating ART, regardless of CD4 count or TB co-infection status (with some exceptions). ### Rationale for TDF + 3TC + EFV 1. **Superior efficacy**: TDF has better potency and barrier to resistance compared to older nucleosides. 2. **Once-daily dosing**: Improves adherence in resource-limited settings. 3. **Cost-effectiveness**: Generic formulations widely available in India. 4. **Tolerability**: EFV is well-tolerated in most patients; neuropsychiatric side effects are manageable with counseling. 5. **Resistance profile**: Lower rates of resistance development compared to older regimens. ### NACP-IV Key Changes from Earlier Guidelines | Feature | NACP-III | NACP-IV | |---------|----------|----------| | **First-line NRTI backbone** | AZT/d4T + 3TC | TDF + 3TC | | **First-line NNRTI** | NVP (CD4 <250 in women) | EFV (universal) | | **Phasing out** | d4T (stavudine) | Zidovudine | | **CD4-based regimen selection** | Yes (NVP vs EFV) | No (universal EFV) | **High-Yield:** NACP-IV moved away from CD4-count-based NNRTI selection. EFV is now standard for all, eliminating the need for CD4 monitoring before ART initiation in resource-limited settings. **Clinical Pearl:** Although this patient has CD4 <200 cells/μL (AIDS-defining), the first-line regimen remains unchanged. Opportunistic infection prophylaxis (cotrimoxazole, fluconazole) is initiated simultaneously, but the ART backbone is standard. ### When Alternatives Are Used - **Integrase inhibitors (DTG-based)**: Reserved for treatment-experienced patients or those with resistance. - **Protease inhibitors (PI-based)**: Second-line; used when NNRTI resistance develops. - **Nevirapine**: No longer recommended as first-line due to higher hepatotoxicity risk, especially in women with CD4 >250 and men with CD4 >400. **Warning:** Stavudine (d4T) has been phased out globally due to mitochondrial toxicity and lipodystrophy; it is no longer part of NACP-IV regimens.